title: Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.
abstract: OBJECTIVE
  To investigate the efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea (IBS-D) and anxiety in a prospective, randomized, controlled study.
  
  
  METHODS
  Two hundred patients with IBS-D and moderate anxiety were randomized to receive pinaverium and tandospirone (arm A) or pinaverium and placebo (arm B). Tandospirone or placebo was given thrice daily at a fixed dose of 10 mg and pinaverium was given thrice daily at a fixed dose of 50 mg. The duration of treatment was 8 wk. Patients were assessed for abdominal pain and diarrhea. Anxiety was evaluated using the Hamilton Rating Scale for Anxiety (HAM-A). The primary study endpoints were response rates for abdominal pain and diarrhea. The secondary study endpoints were response rates for anxiety. Adverse events were also evaluated.
  
  
  RESULTS
  One hundred and seventy of 200 patients (82 patients in arm A and 88 patients in arm B) completed the study. Demographic and baseline characteristics of the 200 participants were comparable in the two arms. At week 8, the overall response rate for abdominal pain and diarrhea was 52.0% for arm A and 37.0% for arm B (P < 0.05). The HAM-A score showed that the response rate was 61.0% for arm A and 21.0% for arm B (P < 0.01). The treatments were well tolerated and no significant adverse events were reported.
  
  
  CONCLUSIONS
  Tandospirone is effective and can be combined with pinaverium in IBS-D patients with anxiety.
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Lan
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Yu-Long
authors.initials: YL
authors.lastname: Chen
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Bai-Ling
authors.initials: BL
authors.lastname: Jia
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Yan-Jun
authors.initials: YJ
authors.lastname: Chu
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Shi-Xiao
authors.initials: SX
authors.lastname: Tang
authors.affiliation: Ling Lan, Hao Zhang, Bai-Ling Jia, Department of Gastroenterology, the People's Hospital, Zhengzhou University, Zhengzhou 450003, Henan Province, China.
authors.forename: Guo-Dong
authors.initials: GD
authors.lastname: Xia
mesh_terms: D015746:Abdominal Pain / Q000188:drug therapy / Q000209:etiology; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002681:China; D003967:Diarrhea / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D054833:Isoindoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D010147:Pain Measurement; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016037:Single-Blind Method; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D002121:Calcium Channel Blockers; D054833:Isoindoles; D009025:Morpholines; D010879:Piperazines; D011743:Pyrimidines; C055267:tandospirone; C013199:pinaverium
keywords: Anxiety; Efficacy; Irritable bowel syndrome; Safety; Tandospirone